Abstract: Provided in one aspect is a pharmaceutical composition for analgesia. The present disclosure relates to a pharmaceutical composition for analgesia that contains an a2 adrenergic receptor antagonist as an active ingredient. In one or more embodiments, the pharmaceutical composition according to the present disclosure is a composition for analgesia through inhibition of an a2 adrenergic receptor, or a composition for analgesia through inhibition of an a2B adrenergic receptor.

Abstract: A pharmaceutical composition for suppressing neuro-inflammation; a pharmaceutical composition for assisting transplantation of neuron precursor cells, pluripotent stem cells, and/or neurons; a pharmaceutical composition for promoting the stabilization of Nrf2 protein in glial cells; a pharmaceutical composition for protecting nerve cells from neuro-inflammation are provided. Provided is a pharmaceutical composition containing, as an active ingredient, a compound having an inhibiting ability against phosphorylation activity of DYRK1A protein, or a pharmaceutically acceptable salt of the compound.

Abstract: A vehicle control device configured to control a vehicle configured to rotate each of four or more drive wheels by each of different motors, includes a motor control unit configured to control torques that are generated by the motors, and when oversteer has occurred during turning of the vehicle, the motor control unit performs a control upon oversteer, and when understeer has occurred during turning of the vehicle, the motor control unit performs a control upon understeer.

Abstract: A novel pharmaceutical composition and method that enable the treatment, amelioration, prevention, and/or suppression of progression of Alzheimer's disease are provided. Provided is a pharmaceutical composition for preventing, treating, suppressing the progression of, and/or ameliorating Alzheimer's disease, the pharmaceutical composition containing, as an active ingredient, a compound that is capable of suppressing the activation or growth of virus in the brain as one of factors that cause the onset or progression of Alzheimer's disease. Also provided is a method for preventing, treating, suppressing the progression of, and/or ameliorating Alzheimer's disease, the method including administering an effective amount of the compound to a subject.

Abstract: A vehicle control device configured to control a vehicle configured to rotate each of four or more drive wheels by each of different motors, includes a motor control unit configured to control torques that are generated by the motors, and when oversteer has occurred during turning of the vehicle, the motor control unit performs a control upon oversteer, and when understeer has occurred during turning of the vehicle, the motor control unit performs a control upon understeer.

Abstract: Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition.

Abstract: A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.

Abstract: Provided is a method capable of suppressing cold damage to a biological material such as an organ even if the biological material is preserved at low temperature for a long time, or a composition for preventing cold damage to a biological material. Provided also is a method for suppressing cold damage to a biological material, including inhibiting a sphingosine-1-phosphoric acid (S1P)-mediated signal transduction pathway in the biological material; and a cold damage prevention composition containing, as an active ingredient, a substance that inhibits S1P-mediated signal transduction pathway.

Abstract: Provided is a method for preventing, ameliorating, suppressing the progression of, and/or treating a tumor caused by a tumor virus, the method including the step of administering, to a subject, an effective amount of a component that targets a gene product of the tumor virus.

Abstract: A method for inducing programmed cell death in cancer cells and a pharmaceutical composition therefor are provided. Provided is a method for inducing programmed cell death in cancer cells, the method including enhancing production of nitric oxide in cancer cells. Provided is a pharmaceutical composition for inducing programmed cell death in cancer cells, the pharmaceutical composition containing, as an active component, a compound that enhances production of nitric oxide in cancer cells. Provided is use of a compound that enhances production of nitric oxide in cancer cells, in a method for preventing, improving, suppressing progression of, and/or treating cancers.

Abstract: A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.

Abstract: A pharmaceutical composition for neovascular diseases, a pharmaceutical composition for inhibiting an angiogenic growth factor, and use of these pharmaceutical compositions are provided. In one or more embodiments, a pharmaceutical composition contains as an active ingredient a low molecular weight compound that is able to suppress the expression of VEGF gene in cells or to reduce the production of VEGF protein from cells. In one or more embodiments, a pharmaceutical composition contains as an active ingredient a compound expressed by the following formula (I) or a prodrug thereof or pharmaceutically acceptable salts thereof.

Abstract: Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition.

Abstract: An engine control device of a vehicle engine includes a processor that detects an operation state of the engine and controls an output of a heater which heats an intake air oxygen concentration sensor detecting oxygen concentration of intake air of the engine. The intake air includes a portion of exhaust gas recirculated to an intake passage of the engine as EGR gas. The processor controls the output of the heater, according to a detected operation state of the engine, so that the intake air oxygen concentration sensor enters one of (i) an active state where a temperature of the intake air oxygen concentration sensor becomes greater than or equal to an activation temperature, (ii) a semi-active state where the sensor temperature is lower than the activation temperature and higher than an inactivation temperature, and (iii) an inactive state where the sensor temperature is lower than the inactivation temperature.

Abstract: Provided is a composition that can be used for an organ preservation solution or perfusate. Alternatively, provided is a composition for prolonging the survival of normal cells and/or a composition for inhibiting the survival of cancer cells. In one or more embodiments, a composition containing, as an active component, a compound that enhances phosphorylation of AMPK (AMP-activated protein kinase). Said composition is one that can prolong the survival of cells (especially, normal cells). Furthermore, said composition is one that can inhibit the survival of cancer cells.

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition.

Abstract: An engine control device of a vehicle engine includes a processor that detects an operation state of the engine and controls an output of a heater which heats an intake air oxygen concentration sensor detecting oxygen concentration of intake air of the engine. The intake air includes a portion of exhaust gas recirculated to an intake passage of the engine as EGR gas. The processor controls the output of the heater, according to a detected operation state of the engine, so that the intake air oxygen concentration sensor enters one of (i) an active state where a temperature of the intake air oxygen concentration sensor becomes greater than or equal to an activation temperature, (ii) a semi-active state where the sensor temperature is lower than the activation temperature and higher than an inactivation temperature, and (iii) an inactive state where the sensor temperature is lower than the inactivation temperature.

Abstract: A compound and a pharmaceutical composition for disease associated with an abnormal splice variant, use of the compound and the pharmaceutical composition, or a screening method of the compound and the pharmaceutical composition are provided. One or more embodiments disclose a compound expressed by the following formula (I) or (I?) or prodrugs or pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition.

Abstract: Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same.